Effect of shikonin on multidrug resistance in HepG2: The role of SIRT1

References

• Ambudkar SV, Dey S, Hrycyna CA, et al. (1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361–98
   PubMed Web of Science ®Google Scholar
• Baldissera VD, de Mattos AA, Coral GP, et al. (2012). Evaluation of the C3435T polymorphism in the MDR1 gene in patients with hepatocellular carcinoma. Ann Hepatol 11:899–906
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Xia W, Wong G. (2009). Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells. J Biol Chem 284:2657–71
   PubMed Web of Science ®Google Scholar
• Brigham LA, Michaels PJ, Flores HE. (1999). Cell-specific production and antimicrobial activity of naphthoquinones in roots of lithospermum erythrorhizon. Plant Physiol 119:417–28
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang B, Wong N, et al. (2011). Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 71:4138–49
   PubMed Web of Science ®Google Scholar
• Chen X, Yang L, Oppenheim JJ, Howard MZ. (2002). Cellular pharmacology studies of shikonin derivatives. Phytother Res: PTR 16:199–209
   PubMed Web of Science ®Google Scholar
• Chen XP, Wang Q, Guan J, et al. (2006). Reversing multidrug resistance by RNA interference through the suppression of MDR1 gene in human hepatoma cells. World J Gastroenterol: WJG 12:3332–7
   PubMed Web of Science ®Google Scholar
• Choi HN, Bae JS, Jamiyandorj U, et al. (2011). Expression and role of SIRT1 in hepatocellular carcinoma. Oncol Rep 26:503–10
   PubMed Web of Science ®Google Scholar
• Chu F, Chou PM, Zheng X, et al. (2005). Control of multidrug resistance gene mdr1 and cancer resistance to chemotherapy by the longevity gene sirt1. Cancer Res 65:10183–7
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Pastan I. (1993). Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385–427
   PubMed Web of Science ®Google Scholar
• Han W, Li L, Qiu S, et al. (2007). Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 6:1641–9
   PubMedGoogle Scholar
• Huang C, Xu D, Xia Q, et al. (2012). Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol 64:1741–50
   PubMed Web of Science ®Google Scholar
• Huang CC, Wu MC, Xu GW, et al. (1992). Overexpression of the MDR1 gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Ins 84:262–4
   PubMed Web of Science ®Google Scholar
• Lee CC, Wang CN, Lai YT, et al. (2010). Shikonin inhibits maturation of bone marrow-derived dendritic cells and suppresses allergic airway inflammation in a murine model of asthma. Br J Pharmacol 161:1496–511
   PubMed Web of Science ®Google Scholar
• Porter AG, Janicke RU. (1999). Emerging roles of caspase-3 in apoptosis. Cell Death Differ 6:99–104
   PubMed Web of Science ®Google Scholar
• Ren YQ, Han JQ, Cao JB, et al. (2012). Association of MDR1 gene polymorphisms with susceptibility to hepatocellular carcinoma in the Chinese population. Asian Pac J Cancer Prev: APJCP 13:5451–4
   PubMedGoogle Scholar
• Shen DW, Lu YG, Chin KV, et al. (1991). Human hepatocellular carcinoma cell lines exhibit multidrug resistance unrelated to MRD1 gene expression. J Cell Sci 98:317–22
   PubMed Web of Science ®Google Scholar
• Singh F, Gao D, Lebwohl MG, Wei H. (2003). Shikonin modulates cell proliferation by inhibiting epidermal growth factor receptor signaling in human epidermoid carcinoma cells. Cancer Lett 200:115–21
   PubMed Web of Science ®Google Scholar
• Staniforth V, Wang SY, Shyur LF, Yang NS. (2004). Shikonins, phytocompounds from Lithospermum erythrorhizon, inhibit the transcriptional activation of human tumor necrosis factor alpha promoter in vivo. J Biol Chem 279:5877–85
   PubMed Web of Science ®Google Scholar
• Wang H, Liu H, Chen K, et al. (2012). SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep 28:311–18
   PubMed Web of Science ®Google Scholar
• Wang H, Wu C, Wan S, et al. (2013). Shikonin attenuates lung cancer cell adhesion to extracellular matrix and metastasis by inhibiting integrin beta1 expression and the ERK1/2 signaling pathway. Toxicology 308:104–12
   PubMed Web of Science ®Google Scholar
• Wu H, Xie J, Pan Q, et al. (2013). Anticancer agent shikonin is an incompetent inducer of cancer drug resistance. PloS One 8:e52706
   Web of Science ®Google Scholar
• Xie Y, Zhang J, Ye S, et al. (2012). SirT1 regulates radiosensitivity of hepatoma cells differently under normoxic and hypoxic conditions. Cancer Sci 103:1238–44
   PubMed Web of Science ®Google Scholar
• Yao Y, Zhou Q. (2010). A novel antiestrogen agent Shikonin inhibits estrogen-dependent gene transcription in human breast cancer cells. Breast Cancer Res Treat 121:233–40
   PubMed Web of Science ®Google Scholar
• Yang H, Zhou P, Huang H, et al. (2009). Shikonin exerts antitumor activity via proteasome inhibition and cell death induction in vitro and in vivo. Int J Cancer 124:2450–9
   PubMed Web of Science ®Google Scholar
• Yingkun N, Lvsong Z, Huimin Y. (2010). Shikonin inhibits the proliferation and induces the apoptosis of human HepG2 cells. Can J Physiol Pharmacol 88:1138–46
   PubMed Web of Science ®Google Scholar
• Zhao BX, Sun YB, Wang SQ, et al. (2013). Grape seed procyanidin reversal of P-glycoprotein associated multi-drug resistance via down-regulation of NF-kappaB and MAPK/ERK mediated YB-1 activity in A2780/T cells. PloS One 8:e71071
   PubMed Web of Science ®Google Scholar
• Zhang YY, Zhou LM. (2013). Omentin-1, a new adipokine, promotes apoptosis through regulating Sirt1-dependent p53 deacetylation in hepatocellular carcinoma cells. Eur J Pharmacol 698:137–44
   PubMed Web of Science ®Google Scholar
• Zhu H, Xia L, Zhang Y, et al. (2012). Activating transcription factor 4 confers a multidrug resistance phenotype to gastric cancer cells through transactivation of SIRT1 expression. PloS One 7:e31431
   PubMed Web of Science ®Google Scholar